Affordable Access

deepdyve-link
Publisher Website

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.

Authors
  • Heymach, J V
  • Lockwood, S J
  • Herbst, R S
  • Johnson, B E
  • Ryan, A J
Type
Published Article
Journal
Annals of Oncology
Publisher
Oxford University Press
Publication Date
Oct 01, 2014
Volume
25
Issue
10
Pages
1941–1948
Identifiers
DOI: 10.1093/annonc/mdu269
PMID: 25057173
Source
Medline
Keywords
License
Unknown

Abstract

NCT00312377.

Report this publication

Statistics

Seen <100 times